Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 4 |
2023 | 3 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.
BMC Cancer. 2023 Oct 23;23(1):1017. doi: 10.1186/s12885-023-11485-y.
BMC Cancer. 2023.
PMID: 37867191
Free PMC article.
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.
Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ.
Wang K, et al.
Future Oncol. 2023 May;19(15):1029-1035. doi: 10.2217/fon-2022-0189. Epub 2023 May 3.
Future Oncol. 2023.
PMID: 37132469
Item in Clipboard
Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study.
Yang SY, Feng JK, Yan ML, Guo L, Duan YF, Ye JZ, Liu ZH, Xiang YJ, Xu L, Xue J, Shi J, Lau WY, Cheng SQ, Guo WX.
Yang SY, et al.
Hepatol Int. 2023 Oct;17(5):1251-1264. doi: 10.1007/s12072-023-10492-2. Epub 2023 Apr 15.
Hepatol Int. 2023.
PMID: 37060489
Item in Clipboard
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.
Guo L, Wei X, Feng S, Zhai J, Guo W, Shi J, Lau WY, Meng Y, Cheng S.
Guo L, et al.
Hepatol Int. 2022 Dec;16(6):1368-1378. doi: 10.1007/s12072-022-10423-7. Epub 2022 Oct 21.
Hepatol Int. 2022.
PMID: 36271176
Clinical Trial.
Item in Clipboard
A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy.
Wang K, Xiang Y, Yan J, Zhu Y, Chen H, Yu H, Cheng Y, Li X, Dong W, Ji Y, Li J, Xie D, Lau WY, Yao J, Cheng S.
Wang K, et al.
Hepatol Int. 2022 Oct;16(5):1188-1198. doi: 10.1007/s12072-022-10393-w. Epub 2022 Aug 24.
Hepatol Int. 2022.
PMID: 36001229
Item in Clipboard
Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.
Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ.
Wang K, et al.
Future Oncol. 2022 Sep;18(30):3367-3375. doi: 10.2217/fon-2022-0188. Epub 2022 Aug 15.
Future Oncol. 2022.
PMID: 35968836
Item in Clipboard
Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.
Xiang YJ, Wang K, Yu HM, Li XW, Cheng YQ, Wang WJ, Feng JK, Bo MH, Qin YY, Zheng YT, Shan YF, Zhou LP, Zhai J, Cheng SQ.
Xiang YJ, et al.
Hepatol Res. 2022 Aug;52(8):721-729. doi: 10.1111/hepr.13773. Epub 2022 May 22.
Hepatol Res. 2022.
PMID: 35536197
Item in Clipboard
Cite
Cite